BrightPath Biotherapeutics Co., Ltd.

TSE:4594 Stock Report

Market Cap: JP¥3.7b

BrightPath Biotherapeutics Management

Management criteria checks 2/4

BrightPath Biotherapeutics' CEO is Kenichi Nagai, appointed in Mar 2011, has a tenure of 13.75 years. directly owns 0.28% of the company’s shares, worth ¥10.32M. The average tenure of the management team and the board of directors is 6.5 years and 9.5 years respectively.

Key information

Kenichi Nagai

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure13.8yrs
CEO ownership0.3%
Management average tenure6.5yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

CEO

Kenichi Nagai (54 yo)

13.8yrs

Tenure

Mr. Kenichi Nagai has been the Chief Executive Officer of BrightPath Biotherapeutics Co., Ltd. (Formerly, GreenPeptide Co., Ltd.) since 2011 and serves as its President since March 2011. Mr. Nagai served a...

Leadership Team

NamePositionTenureCompensationOwnership
Kenichi Nagai
CEO, President & Representative Director13.8yrsno data0.28%
¥ 10.3m
Yoichi Takeshita
CFO & Director1.5yrsno datano data
Norihiro Nakamura
Director of Drug Discovery Research & Director6.5yrsno datano data

6.5yrs

Average Tenure

54yo

Average Age

Experienced Management: 4594's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kenichi Nagai
CEO, President & Representative Director15.9yrsno data0.28%
¥ 10.3m
Yoichi Takeshita
CFO & Director1.5yrsno datano data
Norihiro Nakamura
Director of Drug Discovery Research & Director6.5yrsno datano data
Hirotaka Takeuchi
Independent External Director9.5yrsno datano data
Akira Yamada
Director20.9yrsno data0.22%
¥ 8.0m
Taketoshi Abe
External Auditor15.5yrsno datano data
Yoshiyasu Yamaguchi
External Auditor9.5yrsno datano data
Tsutomu Kishino
Auditor5.5yrsno datano data

9.5yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 4594's board of directors are considered experienced (9.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 11:50
End of Day Share Price 2024/12/26 00:00
Earnings2018/12/31
Annual Earnings2018/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BrightPath Biotherapeutics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution